Protherics, the biopharmaceutical company focused on critical care and oncology,
today announces an agreement with AstraZeneca for the global development and
commercialisation of Protherics' anti-sepsis product CytoFab. CytoFab is currently
being prepared for a single phase III registration study in severe sepsis in
line with guidance received at an end of phase II meeting with the US Food and
Drug Administration (FDA).